(By Balaseshan) Cyberonics Inc. (NASDAQ:CYBX), a medical device company, reported a 17.3% jump in quarterly earnings on growth in both new patients and replacement activity as well as higher sales. Results exceeded Street's expectations, sending its shares up 8.10% in premarket.
Earnings for the first quarter were $8.08 million or $0.29 per share, up from $6.88 million or $0.24 per share last year. Adjusted earnings per share (EPS) climbed to $0.38 from $0.27.
Sales grew 14.5% to $60.32 million. Record worldwide unit sales rose 9% to 3,056, while U.S. epilepsy unit sales increased by an estimated 13%.
Analysts, on average, polled by Thomson Reuters had expected a profit of $0.36 per share on revenue of $58.45 million for the first quarter.
The company's U.S. unit sales increased by 13% to a record of more than 2,300 units and U.S. sales revenue totaling more than $50 million, an increase of 17%.
European unit sales growth was in double digits over the previous year quarter, although overall international unit growth was impacted by slower-than-planned activity in Japan and other international markets.
Overall, international net sales rose to $9.1 million from the $8.9 million, with foreign exchange movements negatively impacting revenue by about $750,000. On a constant currency basis, the increase in international sales was 9.8%.
Looking ahead into the fiscal 2013, the company reaffirmed its adjusted EPS guidance of $1.49 to $1.59 and its sales outlook of $241 million to $244 million, while Street analysts predict EPS of $1.56 on revenue of $243.33 million.
CYBX closed Monday's regular session up 2.12% at $45.33. The stock has been trading between $24.64 and $47.39 for the past 52 weeks.